Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24375328 | 0.81 | GPR119 (0.53) | GPR119METSMARCA2SMARCA4PBRM1 | |
| SCHEMBL28855340 | 0.81 | GPR119 (0.53) | GPR119METSMARCA2SMARCA4PBRM1 | |
| SCHEMBL38661016 | 0.80 | GPR119 (0.58) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL26669234 | 0.80 | GPR119 (0.58) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL38664292 | 0.80 | GPR119 (0.58) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL28515199 | 0.80 | GPR119 (0.55) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL20129677 | 0.80 | GPR119 (0.55) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL20129676 | 0.80 | GPR119 (0.55) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL38653165 | 0.80 | GPR119 (0.52) | GPR119SMARCA2SMARCA4PBRM1LMNA | |
| SCHEMBL22957179 | 0.79 | MAPT (0.53) | GPR119LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPR119 136/4885MET 1419/4885SMARCA2 1204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.